These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 19619692)

  • 1. Adding intravenous unfractionated heparin to standard enoxaparin causes excessive anticoagulation not detected by activated clotting time: results of the STACK-on to ENOXaparin (STACKENOX) study.
    Drouet L; Bal dit Sollier C; Martin J
    Am Heart J; 2009 Aug; 158(2):177-84. PubMed ID: 19619692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are activated clotting times helpful in the management of anticoagulation with subcutaneous low-molecular-weight heparin?
    Henry TD; Satran D; Knox LL; Iacarella CL; Laxson DD; Antman EM
    Am Heart J; 2001 Oct; 142(4):590-3. PubMed ID: 11579347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of unfractionated and low molecular weight heparins on plasma levels of hemostatic factors in patients with acute coronary syndromes.
    Vila V; Martínez-Sales V; Réganon E; Peris E; Perez F; Ruano M; Aznar J
    Haematologica; 2001 Jul; 86(7):729-34. PubMed ID: 11454528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enoxaparin chains stored during chronic treatment are mobilized by a bolus of unfractionated heparin: insights from the STACKENOX study.
    Bal Dit Sollier C; Berge N; Drouet L
    Blood Coagul Fibrinolysis; 2016 Oct; 27(7):779-785. PubMed ID: 26720847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The activated clotting time (ACT) can be used to monitor enoxaparin and dalteparin after intravenous administration.
    Cavusoglu E; Lakhani M; Marmur JD
    J Invasive Cardiol; 2005 Aug; 17(8):416-21. PubMed ID: 16079447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel point-of-care assay for the monitoring of low-molecular weight heparins in the cardiac catheterization laboratory.
    Marmur JD; Lakhani M; El Rouby S; Cavusoglu E
    J Invasive Cardiol; 2008 Sep; 20(9):449-54. PubMed ID: 18762674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioequivalence of generic and branded subcutaneous enoxaparin: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male subjects.
    Feng L; Shen-Tu J; Liu J; Chen J; Wu L; Huang M
    Clin Ther; 2009 Jul; 31(7):1559-67. PubMed ID: 19695405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of anticoagulant and anti-inflammatory responses using enoxaparin versus unfractionated heparin for transesophageal echocardiography-guided cardioversion of atrial fibrillation.
    Hoppensteadt D; Fareed J; Klein AL; Jasper SE; Apperson-Hansen C; Lieber EA; Katz WE; Malouf JF; Stoddard MF; Pape LA;
    Am J Cardiol; 2008 Oct; 102(7):842-6. PubMed ID: 18805108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose tirofiban with enoxaparin and inflammatory markers in high-risk percutaneous intervention.
    Walters DL; Ray MJ; Wood P; Perrin EJ; Bett JH; Aroney CN
    Eur J Clin Invest; 2010 Feb; 40(2):139-47. PubMed ID: 20039931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial.
    Montalescot G; Cohen M; Salette G; Desmet WJ; Macaya C; Aylward PE; Steg PG; White HD; Gallo R; Steinhubl SR;
    Eur Heart J; 2008 Feb; 29(4):462-71. PubMed ID: 18276619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics of a low molecular weight heparin (enoxaparin) after subcutaneous injection, comparison with unfractionated heparin--a three way cross over study in human volunteers.
    Bendetowicz AV; Béguin S; Caplain H; Hemker HC
    Thromb Haemost; 1994 Mar; 71(3):305-13. PubMed ID: 8029794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different effects of enoxaparin and unfractionated heparin on some thrombogenesis markers during hemodialysis: a cross-over study.
    Naumnik B; Pawlak K; Myśliwiec M
    Thromb Res; 2009 Feb; 123(4):631-6. PubMed ID: 18234290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of intravenous enoxaparin in elective percutaneous coronary intervention in patients with renal impairment: results from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial.
    White HD; Gallo R; Cohen M; Steg PG; Aylward PE; Bode C; Steinhubl S; Montalescot G
    Am Heart J; 2009 Jan; 157(1):125-31. PubMed ID: 19081408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of clinically significant pharmacological interactions between ticagrelor and enoxaparin or unfractionated heparin in healthy subjects.
    Teng R; Butler K
    J Clin Pharm Ther; 2012 Dec; 37(6):704-11. PubMed ID: 22747575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of initial nontherapeutic anticoagulation with unfractionated heparin in ST-segment elevation myocardial infarction.
    Cheng S; Morrow DA; Sloan S; Antman EM; Sabatine MS
    Circulation; 2009 Mar; 119(9):1195-202. PubMed ID: 19237657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enoxaparin but not unfractionated heparin causes a dose-dependent increase in plasma TGF-beta 1 during haemodialysis: a cross-over study.
    Naumnik B; Borawski J; Pawlak K; Mysliwiec M
    Nephrol Dial Transplant; 2007 Jun; 22(6):1690-6. PubMed ID: 17389624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Routine use of fondaparinux in acute coronary syndromes: a 2-year multicenter experience.
    Schiele F; Meneveau N; Seronde MF; Descotes-Genon V; Dutheil J; Chopard R; Ecarnot F; Bassand JP;
    Am Heart J; 2010 Feb; 159(2):190-8. PubMed ID: 20152216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion.
    Guervil DJ; Rosenberg AF; Winterstein AG; Harris NS; Johns TE; Zumberg MS
    Ann Pharmacother; 2011 Jul; 45(7-8):861-8. PubMed ID: 21712506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of single bolus anticoagulation with enoxaparin for chronic hemodialysis. Results of an open-label post-certification study.
    Klingel R; Schwarting A; Lotz J; Eckert M; Hohmann V; Hafner G
    Kidney Blood Press Res; 2004; 27(4):211-7. PubMed ID: 15273423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticoagulation monitoring part 2: Unfractionated heparin and low-molecular-weight heparin.
    Spinler SA; Wittkowsky AK; Nutescu EA; Smythe MA
    Ann Pharmacother; 2005; 39(7-8):1275-85. PubMed ID: 15956240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.